|Oral, Intravenous, Vaporized, Insufflated, Suppository|
|Elimination half-life||8 hours|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||177.2456 g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Phenmetrazine (INN, USAN, BAN) (brand name Preludin, and many others) was a stimulant drug that was previously used as an appetite suppressant, but has since been withdrawn from the market. The drug had been widely abused. It was initially replaced by its analogue phendimetrazine (under the brand name Prelu-2) which functions as a prodrug to phenmetrazine, but now it is rarely prescribed, due to concerns of abuse and addiction. Chemically, phenmetrazine is a substituted amphetamine with a morpholine ring.
Phenmetrazine was first patented in Germany in 1952 by Boehringer-Ingelheim, with some pharmacological data published in 1954. It was the result of a search by Thomä and Wick for an anorectic drug without the side-effects of amphetamine. Phenmetrazine was introduced into clinical use in 1954 in Europe.
In clinical use, phenmetrazine produces less nervousness, hyperexcitability, euphoria and insomnia than drugs of the amphetamine family. It tends not to increase heart rate as much as other stimulants. Due to the relative lack of side effects, one study found it well tolerated in children. In a study of the effectiveness on weight loss between phenmetrazine and dextroamphetamine, phenmetrazine was found to be slightly more effective.
Phenmetrazine acts as a releasing agent of norepinephrine and dopamine with EC50 values of 50.4 ± 5.4 nM and 131 ± 11 nM, respectively. It has negligible efficacy as a releaser of serotonin, with an EC50 value of only 7,765 ± 610 nM.
In trials performed on rats, it has been found that after subcutaneous administration of phenmetrazine, both optical isomers are equally effective in reducing food intake, but in oral administration the levo isomer is more effective. In terms of central stimulation however, the dextro isomer is about 4 times as effective in both methods of administration.
The salt which has been used for immediate-release formulations is phenmetrazine hydrochloride (Preludin). Sustained-release formulations were available as resin-bound, rather than soluble, salts. Both of these dosage forms share a similar bioavailability as well as time to peak onset, however, sustained-release formulations offer improved pharmacokinetics with a steady release of active ingredient which results in a lower peak concentration in blood plasma.
1105 g. of 2-phenyl-3-methyl-4-(B-hydroxy ethyl) tetrahydro-1,4-oxazine are dissolved in 4000 cc. of anhydrous toluene. 910 g. of a-phenyl-u-ethyl acetic acid chloride are dissolved in 400 cc. of anhydrous toluene and the resulting solution is slowly added to the heated solution of the tetrahydro-l,4-oxazine compound. The mixture is then heated to boiling for about 5 hours. About 1000 g. of ice are added to the cooled reaction mixture which is then rendered alkaline by the addition of 20% sodium carbonate solution to a pH of 9.0. Thereafter the mixture is vigorously stirred by means of a turbine mixer for one hour and the toluene phase is separated. The toluene solution is washed with 1000 cc. of saturated sodium chloride solution and is dried over anhydrous sodium sulfate. The toluene is then evaporated and the residue is subjected to high vacuum distillation. 1650 g. of a-phenyl-a-ethyl acetic acid-(Z-phenyl- 3-methyl tetrahydro-l,4-oxazine)-N-ethyl ester, boiling at 235-240 C./ 0.05 mm. are obtained thereby in a yield of 90.5% of the theoretical yield.
Its structure incorporates the backbone of amphetamine, the prototypical CNS stimulant which, like phenmetrazine, is a releasing agent of dopamine and norepinephrine. The molecule also loosely resembles ethcathinone, the active metabolite of popular anorectic amfepramone (diethylpropion). Unlike phenmetrazine, ethcathinone (and therefore amfepramone as well) are mostly selective as noradrenaline releasing agents.
Phenmetrazine has been used recreationally in many countries, including Sweden. When stimulant use first became prevalent in Sweden in the 1950s, phenmetrazine was preferred to amphetamine and methamphetamine by users. In the autobiographical novel Rush by Kim Wozencraft, intravenous phenmetrazine is described as the most euphoric and pro-sexual of the stimulants the author used.
Phenmetrazine was classified as a narcotic in Sweden in 1959, and was taken completely off the market in 1965. At first the illegal demand was satisfied by smuggling from Germany, and later Spain and Italy. At first, Preludin tablets were smuggled, but soon the smugglers started bringing in raw phenmetrazine powder. Eventually amphetamine became the dominant stimulant of abuse because of its greater availability.
Phenmetrazine was taken by the Beatles early in their career. Paul McCartney was one known user. McCartney's introduction to drugs started in Hamburg, Germany. The Beatles had to play for hours, and they were often given the drug (referred to as Prellies) by the maid who cleaned their housing arrangements, German customers, or by Astrid Kirchherr (whose mother bought them). McCartney would usually take one, but John Lennon would often take four or five. Hunter Davies asserted, in his 1968 biography of the band, that their use of such stimulants then was in response to their need to stay awake and keep working, rather than a simple desire for kicks.
Preludin was also used recreationally in the US throughout the 1960s and early 1970s. It could be crushed up in water, heated and injected. The street name for the drug in Washington, DC was "Bam". Phenmetrazine continues to be used and abused around the world, in countries including South Korea.
- Substituted phenylmorpholine
- The Beatles drug use in Hamburg
- Boehringer, Albert; Boehringer, Ernst. "Improvements in or relating to the preparation of substituted morpholines" (GB773780).
- US Patent 2835669, Otto Thoma, "Process for the Production of Substituted Morpholines", issued May 20, 1958, assigned to C. H. Boehringer Sohn
- Thomä, O & Wick, H (1954). "Über einige Tetrahydro-1,4-oxazine mit sympathicomimetischen Eigenschaften". Arch. Exp. Pathol. Pharmakol. 222: 540.
- Martel, Antonio (1957). "Preludin (Phenmetrazine) in the Treatment of Obesity". Can. Med. Assoc. J. 76 (2): 117–20. PMC 1823494. PMID 13383418.
- Kalant, Oriana Josseau (1966). The Amphetamines: Toxicity and Addiction. ISBN 0-398-02511-8.
- "Phenmetrazine Hydrochloride". J. Am. Med. Assoc. 163 (5): 357. 1957.
- Hampson, J; Loraine, J.A.; Strong, J.A. (1960). "Phenmetrazine and Dexamphetamine in the Management of Obesity". The Lancet. 275 (7137): 1265–7. doi:10.1016/S0140-6736(60)92250-9. PMID 14399386.
- Rothman RB, Baumann MH (2006). "Therapeutic potential of monoamine transporter substrates". Current Topics in Medicinal Chemistry. 6 (17): 1845–59. doi:10.2174/156802606778249766. PMID 17017961. Archived from the original on 2017-03-26. Retrieved 2020-05-05.
- Anthony C Moffat, M David Osselton and Brian Widdop. Clarke's Analysis of Drugs and Poisons. ISBN 0-85369-473-7.
- Engelhardt, A (1961). "Studies of the Mechanism of the Anti-Appetite Action of Phenmetrazine". Biochem. Pharmacol. 8 (1): 100. doi:10.1016/0006-2952(61)90520-2.
- https://www.google.com/patents/US3018222 US3018222]|date=January 2015
- Brecher, Edward M. "The Swedish Experience". Retrieved 2009-10-31.
- Miles, Barry (1998). Paul McCartney: Many Years from Now. pp. 66–67. ISBN 0-8050-5248-8.
- Davies, Hunter (1968). The Beatles: The Authorized Biography. p. 78. ISBN 0-07-015457-0.
- Ruby, Jack (1964). Testimony of Jack Ruby. 5. Washington: US Government Printing Office. pp. 198–99.
- Dash, Leon (1996). Rosa Lee. HarperCollins. p. 109.
- Choi H, Baeck S, Jang M, Lee S, Choi H, Chung H (10 February 2012). "Simultaneous analysis of psychotropic phenylalkylamines in oral fluid by GC-MS with automated SPE and its application to legal cases". Forensic Science International. 215 (1–3): 81–87. doi:10.1016/j.forsciint.2011.02.011. PMID 21377815.